Lantheus Holdings, Inc. (LNTH)
USD 101.24
(0.71%)
USD 101.24
(0.71%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 364.64 Million USD | 2813.72% |
| 2022 | -13.43 Million USD | 82.34% |
| 2021 | -76.08 Million USD | -1712.48% |
| 2020 | -4.19 Million USD | -113.09% |
| 2019 | 32.06 Million USD | -50.28% |
| 2018 | 64.48 Million USD | 24.37% |
| 2017 | 51.85 Million USD | -8.37% |
| 2016 | 56.58 Million USD | 33.05% |
| 2015 | 42.53 Million USD | 7.9% |
| 2014 | 39.41 Million USD | 308.65% |
| 2013 | -18.89 Million USD | -2418.8% |
| 2012 | -750 Thousand USD | 95.66% |
| 2011 | -17.28 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 102.62 Million USD | 2.24% |
| 2024 Q1 | 100.38 Million USD | -26.99% |
| 2023 Q2 | 124.13 Million USD | 1428.54% |
| 2023 Q1 | -9.34 Million USD | 94.56% |
| 2023 FY | 364.64 Million USD | 2813.72% |
| 2023 Q4 | 137.48 Million USD | 22.36% |
| 2023 Q3 | 112.36 Million USD | -9.49% |
| 2022 Q4 | -171.67 Million USD | -300.22% |
| 2022 Q1 | 58.92 Million USD | 266.75% |
| 2022 Q2 | 63.2 Million USD | 7.26% |
| 2022 Q3 | 85.74 Million USD | 35.66% |
| 2022 FY | -13.43 Million USD | 82.34% |
| 2021 FY | -76.08 Million USD | -1712.48% |
| 2021 Q1 | 15.62 Million USD | 3058.71% |
| 2021 Q3 | -14.32 Million USD | 46.5% |
| 2021 Q4 | -35.33 Million USD | -146.64% |
| 2021 Q2 | -26.78 Million USD | -271.43% |
| 2020 Q4 | -528 Thousand USD | 89.94% |
| 2020 Q3 | -5.25 Million USD | 5.32% |
| 2020 FY | -4.19 Million USD | -113.09% |
| 2020 Q2 | -5.54 Million USD | -177.82% |
| 2020 Q1 | 7.12 Million USD | -42.72% |
| 2019 Q4 | 12.43 Million USD | 46.04% |
| 2019 Q1 | 16.16 Million USD | -4.57% |
| 2019 Q2 | 14.53 Million USD | -10.09% |
| 2019 FY | 32.06 Million USD | -50.28% |
| 2019 Q3 | 8.51 Million USD | -41.41% |
| 2018 Q2 | 15.92 Million USD | 5.21% |
| 2018 FY | 64.48 Million USD | 24.37% |
| 2018 Q1 | 15.13 Million USD | 64.41% |
| 2018 Q4 | 16.94 Million USD | 2.8% |
| 2018 Q3 | 16.48 Million USD | 3.49% |
| 2017 FY | 51.85 Million USD | -8.37% |
| 2017 Q3 | 12.82 Million USD | -28.36% |
| 2017 Q2 | 17.89 Million USD | 50.05% |
| 2017 Q1 | 11.92 Million USD | -1.76% |
| 2017 Q4 | 9.2 Million USD | -28.19% |
| 2016 Q2 | 14.17 Million USD | -19.77% |
| 2016 FY | 56.58 Million USD | 33.05% |
| 2016 Q4 | 12.14 Million USD | -3.6% |
| 2016 Q1 | 17.67 Million USD | 42.66% |
| 2016 Q3 | 12.59 Million USD | -11.17% |
| 2015 Q2 | 5.35 Million USD | -52.93% |
| 2015 Q1 | 11.37 Million USD | -2.98% |
| 2015 Q3 | 13.4 Million USD | 150.34% |
| 2015 FY | 42.53 Million USD | 7.9% |
| 2015 Q4 | 12.38 Million USD | -7.61% |
| 2014 Q2 | 9.98 Million USD | 17.56% |
| 2014 FY | 39.41 Million USD | 308.65% |
| 2014 Q4 | 11.72 Million USD | 27.18% |
| 2014 Q3 | 9.22 Million USD | -7.61% |
| 2014 Q1 | 8.48 Million USD | 736.36% |
| 2013 FY | -18.89 Million USD | -2418.8% |
| 2013 Q1 | -9.23 Million USD | -924.64% |
| 2013 Q2 | -3.75 Million USD | 59.37% |
| 2013 Q3 | -4.56 Million USD | -21.72% |
| 2013 Q4 | -1.33 Million USD | 70.8% |
| 2012 FY | -750 Thousand USD | 95.66% |
| 2012 Q4 | 1.12 Million USD | 0.0% |
| 2011 FY | -17.28 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | -118.4% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 14597.437% |
| Embecta Corp. | 221.5 Million USD | -64.624% |
| Pacira BioSciences, Inc. | 87.67 Million USD | -315.902% |
| PainReform Ltd. | -9.58 Million USD | 3904.695% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 7720.046% |
| SCYNEXIS, Inc. | 72.66 Million USD | -401.785% |
| Journey Medical Corporation | -2.07 Million USD | 17690.063% |
| Safety Shot Inc | -12.18 Million USD | 3092.757% |
| Alpha Teknova, Inc. | -35.56 Million USD | 1125.341% |
| Bright Green Corporation | -8.89 Million USD | 4201.073% |
| Procaps Group, S.A. | 38.97 Million USD | -835.627% |
| Alvotech | -354.86 Million USD | 202.757% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | -676.313% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 2514.528% |
| Cosmos Health Inc. | -21.83 Million USD | 1770.278% |
| Dynavax Technologies Corporation | -37.02 Million USD | 1084.774% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 334.401% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 328.786% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 7720.046% |
| Theratechnologies Inc. | -10.62 Million USD | 3531.279% |
| Harrow Health, Inc. | 580 Thousand USD | -62769.31% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 7856.69% |
| Biofrontera Inc. | -22.67 Million USD | 1707.982% |
| DURECT Corporation | -36.88 Million USD | 1088.618% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 7020.516% |
| Cronos Group Inc. | -81.37 Million USD | 548.098% |
| OptiNose, Inc. | -22.74 Million USD | 1702.963% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | -74.44% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 1031.326% |
| RedHill Biopharma Ltd. | 12.63 Million USD | -2786.653% |
| Organogenesis Holdings Inc. | 12.52 Million USD | -2811.313% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | 8509.025% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 5971.078% |
| Radius Health, Inc. | -3.92 Million USD | 9390.242% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 10439.251% |
| ProPhase Labs, Inc. | -21.61 Million USD | 1787.142% |
| Phibro Animal Health Corporation | 53.31 Million USD | -583.939% |
| Procaps Group S.A. | 52.32 Million USD | -596.892% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 4378.329% |
| Viatris Inc. | 766.2 Million USD | 52.409% |
| Rockwell Medical, Inc. | -6.67 Million USD | 5566.897% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 7040.274% |
| SIGA Technologies, Inc. | 83.62 Million USD | -336.064% |
| Tilray Brands, Inc. | -174.74 Million USD | 308.671% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | -3807.856% |
| Shineco, Inc. | -17.06 Million USD | 2236.674% |
| PetIQ, Inc. | 60.01 Million USD | -507.585% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 7798.186% |
| Incannex Healthcare Limited | -30.04 Million USD | 1313.814% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | -45.334% |
| Alimera Sciences, Inc. | -1.47 Million USD | 24888.715% |
| Silver Spike Investment Corp. | 7.34 Million USD | -4867.8% |
| Assertio Holdings, Inc. | -243.53 Million USD | 249.728% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 6288.365% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 2777.772% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 2438.348% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 1918.658% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 364.523% |
| Hempacco Co., Inc. | -8.81 Million USD | 4237.885% |
| Talphera, Inc. | -16.88 Million USD | 2259.05% |
| Alvotech | -354.86 Million USD | 202.757% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | -582.16% |
| Currenc Group, Inc. | -6.64 Million USD | 5586.816% |
| Kamada Ltd. | 10.06 Million USD | -3523.231% |
| Indivior PLC | -4 Million USD | 9216.05% |
| Evoke Pharma, Inc. | -7.43 Million USD | 5007.11% |
| Flora Growth Corp. | -50.35 Million USD | 824.157% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 1918.658% |
| Evolus, Inc. | -49.23 Million USD | 840.646% |
| HUTCHMED (China) Limited | 18.37 Million USD | -1884.446% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | -85.11% |
| Akanda Corp. | -10.05 Million USD | 3727.783% |